Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $153,450.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 15,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $153,450.00. Following the completion of the sale, the insider owned 1,584,208 shares of the company’s stock, valued at approximately $16,206,447.84. The trade was a 0.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Thursday, November 5th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $12.49, for a total value of $312,250.00.
• On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total transaction of $141,150.00.
• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $10.00, for a total value of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total transaction of $127,350.00.

Xeris Biopharma Price Performance

Shares of XERS opened at $15.20 on Friday. The firm has a market capitalization of $2.77 billion, a PE ratio of -303.94 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $15.21. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The stock’s 50 day moving average is $9.62 and its two-hundred day moving average is $7.62.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business had revenue of $107.23 million during the quarter, compared to analyst estimates of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vilga Financial Planning LLC acquired a new position in Xeris Biopharma in the 3rd quarter valued at $10,134,000. Legal & General Group Plc purchased a new position in shares of Xeris Biopharma in the second quarter valued at $15,941,000. Walleye Capital LLC purchased a new stake in shares of Xeris Biopharma in the 2nd quarter worth approximately $4,841,000. Canada Pension Plan Investment Board purchased a new stake in shares of Xeris Biopharma in the second quarter worth about $1,736,000. Finally, Bank of America Corp DE acquired a new stake in shares of Xeris Biopharma in the second quarter valued at approximately $11,065,000. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Analyst Ratings Changes

XERS has been the subject of several research reports. Leerink Partners upped their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. HC Wainwright increased their target price on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Oppenheimer reiterated an “outperform” rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a report on Friday. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.20.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.